In addition to this, a phase I trial involving patients with HER2-positive cancer including HNSCCs, utilizing CAdVEC (a genetically modified oncolytic viral strain of human adenovirus (Ad) with potential immunostimulating and antineoplastic activities) coupled with HER2-specific CAR-T cells, is in recruitment (NCT03740256). Here, ERBB2 is linked to cancer.